#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review in Japan. This marks an important step towards addressing the global burden of CHB. We are committed to reshaping the treatment landscape for people living with CHB. Learn more: https://gsk.to/3OzlPIO
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- London, England
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
News for #Investors and #Media: Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies. 🔗 Find out more on our website: https://gsk.to/4r0JkrM
-
#News for #investors and #media: We have entered an agreement to acquire 35Pharma. Find out more: https://gsk.to/4aAHJUD #GSK #AheadTogether
-
In the mid-1990s, Dr Kimberly Smith diagnosed Beth, her patient, with AIDS after she was admitted to hospital with pneumonia. Not only did Beth have difficulty tolerating her medicines, but she also lived in fear of her diagnosis, especially after she adopted a son. Her wish – in addition to living a healthy life – was to be able to see him graduate from university. Today, Beth is thriving, healthy – and, most importantly for her, she made it to her son’s graduation. A turning point in her success, she shared, was in large part because of a long-acting therapy she had access to. In this Behind the Science article, Dr Smith describes the huge impact her Research and Development team at ViiV Healthcare have made – and will continue to make – for patients, and just how far their ambitions go. 🔗 https://gsk.to/40giwZr
-
-
HIV remains one of the world’s biggest health threats. While great strides have been made in HIV treatment, with people living with HIV on effective treatment able to live long and full lives, stigma remains a challenge. Fear of harsh judgement and discrimination associated with HIV can prevent many people from getting tested and diagnosed, as well as starting and staying on treatment. Find out how we are addressing these barriers by minimising the impact of HIV on people’s lives through treatment, prevention and ultimately cure: 🔗 https://gsk.to/4tDaHux #CROI2026
-
Respiratory syncytial virus, or RSV, is a common virus that spreads easily through droplets and close contact, affecting the lungs and breathing passages. RSV can cause difficulty breathing and can result in serious illness and hospitalisation, especially among young children, older adults and people with underlying health conditions. Every year in Europe, RSV leads to around 213,000 hospitalisations in children under five and around 158,000 hospitalisations in adults. This audiogram is taken from a recent advisory board that brought together individuals living with chronic respiratory conditions, as well as those who have experienced a severe episode of RSV, to share their lived experiences and personal perspectives. For more than 50 years, GSK has been advancing research to help patients protect themselves from infectious diseases such as RSV. As a leader in this field, we continue to invest in new approaches that aim to prevent severe illness, hospitalisation, and support the health of people living with certain chronic health conditions. #AheadTogether #RSVVW26
-
News for #Investors and #Media: New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges. 🔗 Find out more on our website: https://gsk.to/3ZKiNDN
-
The #AMR2026 Summit in Sydney calls out the critical role that young scientists and innovators play in responding to #AntimicrobialResistance (AMR) and safeguarding our antibiotics. We couldn’t agree more. Hear why in our ‘Behind the Science’ podcast episode ‘Are we turning the tide on superbugs?’. In this episode host Dr Kat Arney, and guests Alison Holmes (Fleming Initiative) and our Head of Infectious Disease Research David Payne discuss all things AMR, from the solutions being developed to why infectious disease research is the place to be. Tune into the full podcast to hear more: https://gsk.to/4kB46wk #BTSPodcast
Available Now
-
#News for #Investors and #Media: Today we are presenting new data about one of our vaccines. Learn more: https://gsk.to/3MAH4cn
-
#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases. Learn more here: https://gsk.to/3ZJckZR